StreetInsider.com News Articles

StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 18:00:32 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Takeda psoriasis drug shows skin clearance in Phase 3 trials http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html <p>Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The data were presented at the 2026 American Academy of Dermatology Innovation Academy.</p> <p>The LATITUDE PsO 3001 and 3002 studies evaluated skin clearance at hard-to-treat sites including the scalp, nails, and palms and soles. In the scalp, 77% and 74% of patients treated with zasocitinib achieved clear or almost clear skin at week 16, compared with 7% and 13% for placebo and 42% and 30% for apremilast. For palmoplantar http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html Thu, 16 Jul 2026 18:00:32 -0400 4502 O.00987337 O.05065998 TAK Takeda psoriasis drug shows skin clearance in Phase 3 trials http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html <p>Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The data were presented at the 2026 American Academy of Dermatology Innovation Academy.</p> <p>The LATITUDE PsO 3001 and 3002 studies evaluated skin clearance at hard-to-treat sites including the scalp, nails, and palms and soles. In the scalp, 77% and 74% of patients treated with zasocitinib achieved clear or almost clear skin at week 16, compared with 7% and 13% for placebo and 42% and 30% for apremilast. For palmoplantar http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html Thu, 16 Jul 2026 18:00:32 -0400 4502 O.00987337 O.05065998 TAK Takeda psoriasis drug shows skin clearance in Phase 3 trials http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html <p>Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The data were presented at the 2026 American Academy of Dermatology Innovation Academy.</p> <p>The LATITUDE PsO 3001 and 3002 studies evaluated skin clearance at hard-to-treat sites including the scalp, nails, and palms and soles. In the scalp, 77% and 74% of patients treated with zasocitinib achieved clear or almost clear skin at week 16, compared with 7% and 13% for placebo and 42% and 30% for apremilast. For palmoplantar http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html Thu, 16 Jul 2026 18:00:32 -0400 4502 O.00987337 O.05065998 TAK Takeda psoriasis drug shows skin clearance in Phase 3 trials http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html <p>Takeda Pharmaceutical (TSE: 4502 / NYSE: TAK) announced secondary endpoint data from two Phase 3 studies of zasocitinib, an investigational oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The data were presented at the 2026 American Academy of Dermatology Innovation Academy.</p> <p>The LATITUDE PsO 3001 and 3002 studies evaluated skin clearance at hard-to-treat sites including the scalp, nails, and palms and soles. In the scalp, 77% and 74% of patients treated with zasocitinib achieved clear or almost clear skin at week 16, compared with 7% and 13% for placebo and 42% and 30% for apremilast. For palmoplantar http://www.streetinsider.com/FDA/Takeda+psoriasis+drug+shows+skin+clearance+in+Phase+3+trials/26780782.html Thu, 16 Jul 2026 18:00:32 -0400 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Press+Releases/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html <ul class="bwlistdisc"> <li> On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 </li> <li> Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo </li> <li> Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill </li> </ul> <p> OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda <b>(</b><a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.takeda.com%2Finvestors%2Foverview%2F&esheet=54571620&newsitemid=20260716820927&lan=en-US&anchor=TSE%3A4502%2FNYSE%3ATAK&index=1&md5=93d582460ae2ab4a4cb47a5ce74d9241" shape="rect"><b>TSE:4502/NYSE:TAK</b></a><b>)</b> announced new data from the two pivotal Phase 3 studies of zasocitinib http://www.streetinsider.com/Business+Wire/Takeda%E2%80%99s+Zasocitinib+Demonstrates+Consistent%2C+High+Rates+of+Skin+Clearance+Across+the+Body%2C+Including+Hard-to-Treat+and+High-Impact+Sites%2C+in+Phase+3+Psoriasis+Studies/26780778.html Thu, 16 Jul 2026 18:00:00 -0400 4502 4502 O.00987337 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Pignagnoli+Agosti+Marcello/26759297.html si-local-file:///var/storage/secattach/20260713/26759297.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Pignagnoli+Agosti+Marcello/26759297.html Mon, 13 Jul 2026 06:27:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Pignagnoli+Agosti+Marcello/26759297.html si-local-file:///var/storage/secattach/20260713/26759297.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Pignagnoli+Agosti+Marcello/26759297.html Mon, 13 Jul 2026 06:27:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Pignagnoli Agosti Marcello http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Pignagnoli+Agosti+Marcello/26759297.html si-local-file:///var/storage/secattach/20260713/26759297.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Pignagnoli+Agosti+Marcello/26759297.html Mon, 13 Jul 2026 06:27:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Platford+Giles+Richard/26759289.html si-local-file:///var/storage/secattach/20260713/26759289.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Platford+Giles+Richard/26759289.html Mon, 13 Jul 2026 06:26:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Platford+Giles+Richard/26759289.html si-local-file:///var/storage/secattach/20260713/26759289.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Platford+Giles+Richard/26759289.html Mon, 13 Jul 2026 06:26:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Platford Giles Richard http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Platford+Giles+Richard/26759289.html si-local-file:///var/storage/secattach/20260713/26759289.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Platford+Giles+Richard/26759289.html Mon, 13 Jul 2026 06:26:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Duprey+Lauren+Rusckowski/26759292.html si-local-file:///var/storage/secattach/20260713/26759292.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Duprey+Lauren+Rusckowski/26759292.html Mon, 13 Jul 2026 06:26:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Duprey+Lauren+Rusckowski/26759292.html si-local-file:///var/storage/secattach/20260713/26759292.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Duprey+Lauren+Rusckowski/26759292.html Mon, 13 Jul 2026 06:26:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Duprey Lauren Rusckowski http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Duprey+Lauren+Rusckowski/26759292.html si-local-file:///var/storage/secattach/20260713/26759292.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Duprey+Lauren+Rusckowski/26759292.html Mon, 13 Jul 2026 06:26:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Ricci+Gabriele/26759284.html si-local-file:///var/storage/secattach/20260713/26759284.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Ricci+Gabriele/26759284.html Mon, 13 Jul 2026 06:25:00 -0400 4502 O.05065998 TAK Form 144 TAKEDA PHARMACEUTICAL Filed by: Ricci Gabriele http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Ricci+Gabriele/26759284.html si-local-file:///var/storage/secattach/20260713/26759284.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++TAKEDA+PHARMACEUTICAL++++++++++++++++++Filed+by%3A+Ricci+Gabriele/26759284.html Mon, 13 Jul 2026 06:25:00 -0400 4502 O.05065998 TAK